Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Current Psychiatry Reports
Published in: Current Psychiatry Reports 7/2013

Open Access 01-07-2013 | Attention-Deficit Disorder (R Bussing, Section Editor)

Enhancing ADHD Medication Adherence: Challenges and Opportunities

Authors: Alice Charach, Rebeca Fernandez

Published in: Current Psychiatry Reports | Issue 7/2013

Login to get access

Abstract

Safe and effective medication for attention deficit hyperactivity disorder (ADHD) is available and recommended as first-line treatment for the core symptoms of inattention, overactivity and impulsiveness. Despite impaired functioning during adolescence, many discontinue medication treatment. For children, healthcare decisions are usually made by the parent; older youth make their own decisions. Beliefs and attitudes may differ widely. Some families understand that ADHD is a neurobiological condition and accept that medication is indicated, for others, such treatment is unacceptable. Converging evidence describes negative perceptions of the burden associated with medication use as well as concerns about potential short and long term adverse effects. Indeed experiences of adverse effects are a frequent explanation for discontinuation among youth. Ways to improve shared decision making among practitioners, parents and youth, and to monitor effectiveness, safety and new onset of concurrent difficulties are likely to optimize outcomes.
Literature
1.
Charach A, Dashti B, Carson P, Booker L, Lim CG, Lillie E, et al. Attention deficit hyperactivity disorder: effectiveness of treatment in at-risk preschoolers; long-term effectiveness in all ages; and variability in prevalence, diagnosis, and treatment. Rockville (MD): Agency for healthcare research and quality (US); 2011. Report No.: 12-EHC003-EF.
2.
Biederman J et al. New insights into the comorbidity between ADHD and major depression in adolescent and young adult females. J Am Acad Child Adolesc Psychiatry. 2008;47(4):426–34.PubMedCrossRef
3.
Biederman J et al. Are girls with ADHD at risk for eating disorders? Results from a controlled, five-year prospective study. J Dev Behav Pediatr. 2007;28(4):302–7.PubMedCrossRef
4.
Barkley RA et al. Young adult outcome of hyperactive children: adaptive functioning in major life activities. J Am Acad Child Adolesc Psychiatr. 2006;45(2):192–202.CrossRef
5.
Reimer B et al. The impact of distractions on young driverswith attention deficit hyperactivity disorder (ADHD). Accid Anal Prev. 2010;42(3):842–51.PubMedCrossRef
6.
Faregh N, Derevensky J. Gambling behavior among adolescents with attention deficit/hyperactivity disorder. J Gambl Stud. 2011;27(2):243–56.PubMedCrossRef
7.
Murray DW et al. A clinical review of outcomes of the multimodal treatment study of children with attention-deficit/hyperactivity disorder (MTA). Curr Psychiatry Rep. 2008;10(5):424–31.PubMedCrossRef
8.
Barbaresi WJ, Katusic SK, Colligan RC. Modifiers of long-term school outcomes for children with attention-deficit/hyperactivity disorder: does treatment with stimulant medication make a difference? Results from a population-based study. J Dev Behav Pediatr. 2007;28(4):274–87.PubMedCrossRef
9.
Biederman J et al. Do stimulants protect against psychiatric disorders in youth with ADHD? A 10-year follow-up study. Pediatrics. 2009;124(1):71–8.PubMedCrossRef
10.
Wilens TE et al. Effect of prior stimulant treatment for attention-deficit/hyperactivity disorder on subsequent risk for cigarette smoking and alcohol and drug use disorders in adolescents. Arch Pediatr Adolesc Med. 2008;162(10):916–21.PubMedCrossRef
11.
Lichtenstein P et al. Medication for attention deficit-hyperactivity disorder and criminality. N Engl J Med. 2012;367(21):2006–14.PubMedCrossRef
12.
Charach A, Gajaria A. Improving psychostimulant adherence in children with ADHD. Expert Rev Neurother. 2008;8(10):1563–71.PubMedCrossRef
13.
Charach A, Ickowicz A, Schachar R. Stimulant treatment over five years: adherence, effectiveness, and adverse effects. J Am Acad Child Adolesc Psychiatr. 2004;43(5):559–67.CrossRef
14.
The MTA cooperative group. A 14 month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 1999;56:1073–1086.
15.
AACAP. Practice, parameter for the use of stimulant medications in the treatment of children, adolescents and adults. J Am Acad Child Adolesc. 2002;41(2 Suppl):26S–49.
16.
Meaux JB et al. Stimulant medications: a trade-off? The lived experience of adolescents with ADHD. J Spec Pediatr Nurs. 2006;11(4):214–26.PubMedCrossRef
17.
Barbaresi WJ et al. Long-term stimulant medication treatment of attention-deficit/hyperactivity disorder: results from a population-based study. J Dev Behav Pediatr. 2006;27(1):1–10.PubMedCrossRef
18.
Hirshfeld DR et al. Expressed emotion toward children with behavioral inhibition: associations with maternal anxiety disorder. J Am Acad Child Adolesc Psychiatr. 1997;36(7):910–7.CrossRef
19.
Parens E, Johnston J. Facts, values, and attention-deficit hyperactivity disorder (ADHD): an update on the controversies. Child Adolesc Psychiatr Ment Health. 2009;3(1):1.CrossRef
20.
Lahey BB et al. Predictive validity of ICD-10 hyperkinetic disorder relative to DSM-IV attention-deficit/hyperactivity disorder among younger children. J Child Psychol Psychiatry. 2006;47(5):472–9.PubMedCrossRef
21.
Bloom B, Cohen RA, Freeman G. Summary health statistics for U.S. children: National Health Interview Survey, 2007. Vital Health Stat. 2009;10(239):1–80.
22.
Hudson JL, Miller GE, Kirby JB. Explaining racial and ethnic differences in children's use of stimulant medications. Med Care. 2007;45(11):1068–75.PubMedCrossRef
23.
Williams J, Taylor E. The evolution of hyperactivity, impulsivity and cognitive diversity. J R Soc Interface. 2006;47(5):472–9.
24.
Stevens J, Harman JS, Kelleher KJ. Race/ethnicity and insurance status as factors associated with ADHD treatment patterns. J Child Adolesc Psychopharmacol. 2005;15(1):88–96.PubMedCrossRef
25.
Gau SS et al. An open-label, randomized, active-controlled equivalent trial of osmotic release oral system methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan. J Child Adolesc Psychopharmacol. 2006;16(4):441–55.PubMedCrossRef
26.
Steele M et al. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder. Can J Clin Pharmacol. 2006;13(1):e50–62.PubMed
27.
Chen CY, Gerhard T, Winterstein AG. Determinants of initial pharmacological treatment for youths with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009;19(2):187–95.PubMedCrossRef
28.
Olfson M, Marcus S, Wan G. Stimulant dosing for children with ADHD: a medical claims analysis. J Am Acad Child Adolesc Psychiatr. 2009;48(1):51–9.CrossRef
29.
Miller AR et al. Prescription of methylphenidate to children and youth, 1990-1996. CMAJ. 2001;165(11):1489–94.PubMed
30.
Marcus SC et al. Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med. 2005;159(6):572–8.PubMedCrossRef
31.
Faraone SV, Giefer EE. Long-term effects of methylphenidate transdermal delivery system treatment of ADHD on growth. J Am Acad Child Adolesc Psychiatr. 2007;46(9):1138–47.CrossRef
32.
• Gearing RE et al. Reconceptualizing medication adherence: six phases of dynamic adherence. Harv Rev Psychiatr. 2011;19(4):177–89. This article describes a six-phase model of transactional processes and other factors that influence patients' medication adherence decisions, placing the patient–provider relationship as central to the process.CrossRef
33.
•• Bussing R et al. Willingness to use ADHD treatments: a mixed methods study of perceptions by adolescents, parents, health professionals and teachers. Soc Sci Med. 2012;74(1):92–100. This study describes overall perceptions of relative burden of several commonly used interventions (medication, behavior therapy, psychoeducation, counseling) for ADHD.PubMedCrossRef
34.
DosReis S et al. Parental attitudes in psychopharmacological treatment for ADHD: a conceptual model. Int Rev Psychiatr. 2008;20(2):135–41.CrossRef
35.
DosReis S et al. The meaning of attention-deficit/hyperactivity disorder medication and parents' initiation and continuity of treatment for their child. J Child Adolesc Psychopharmacol. 2009;19(4):377–83.PubMedCrossRef
36.
Bussing R, Gary FA. Practice guidelines and parental ADHD treatment evaluations: friends or foes? Harv Rev Psychiatr. 2001;9(5):223–33.CrossRef
37.
Johnston C, Hommersen P, Seipp C. Acceptability of behavioral and pharmacological treatments for attention-deficit/hyperactivity disorder: relations to child and parent characteristics. Behav Ther. 2008;39(1):22–32.PubMedCrossRef
38.
Coletti DJ et al. Parent perspectives on the decision to initiate medication treatment of attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2012;22(3):226–37.PubMedCrossRef
39.
Corkum P, Rimer P, Shachar R. Parental knowledge of attention-deficit/hyperactivity disorder and opinions of treatment option: impact on enrollment and adherence to a 12-month treatment trial. Can J Psychiatr Rev Canad Psychiatr. 1999;44(10):1043–8.
40.
Gau SS et al. Determinants of adherence to methylphenidate and the impact of poor adherence on maternal and family measures. J Child Adolesc Psychopharmacol. 2006;16(3):286–97.PubMedCrossRef
41.
Kendall J et al. Children's Accounts of attention-deficit/hyperactivity disorder. ANS Adv Nurs Sci. 2003;26(2):114–30.PubMed
42.
Singh I, Kendall T, Taylor C. Young People’s experience of ADHD and stimulant medication: a qualitative study for the NICE guideline. Child Adolesc Ment Health. 2010;15(4):186–92.CrossRef
43.
Toomey SL et al. Why do children with ADHD discontinue their medication? Clin Pediatr (Phila). 2012;51(8):763–9.CrossRef
44.
•• Bussing R et al. Receiving treatment for attention-deficit hyperactivity disorder: do the perspectives of adolescents matter? J Adolesc Health. 2011;49(1):7–14. This study documents differences and factors contributing to those differences between adolescent and parent perspectives on receiving treatment for ADHD.PubMedCrossRef
45.
Fiks G, Hughes C, Gafen A. Contrasting parents’ and pediatricians’ perspectives on shared-decision making in ADHD. Pediatrics. 2011;127:e188–96.PubMedCrossRef
46.
Fiks AG et al. Shared decision-making and health care expenditures among children with special health care needs. Pediatrics. 2012;129(1):99–107.PubMedCrossRef
47.
Fiks AG et al. Shared decision-making in pediatrics: a national perspective. Pediatrics. 2010;126(2):306–14.PubMedCrossRef
48.
Newcorn JH et al. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry. 2008;165(6):721–30.PubMedCrossRef
49.
Abikoff HB et al. Methylphenidate effects on functional outcomes in the preschoolers with attention-deficit/hyperactivity disorder treatment study (PATS). J Child Adolesc Psychopharmacol. 2007;17(5):581–92.PubMedCrossRef
50.
Mosholder AD et al. Hallucinations and other psychotic symptoms associated with the use of attention-deficit/hyperactivity disorder drugs in children. Pediatrics. 2009;123(2):611–6.PubMedCrossRef
51.
Bangs ME et al. Meta-analysis of suicide-related behavior events in patients treated with atomoxetine. J Am Acad Child Adolesc Psychiatr. 2008;47(2):209–18.CrossRef
52.
Wolraich M, Brown L, Brown RT, DuPaul G, Earls M, Feldman HM, et al. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention‐deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2011;128(5):1007–22.
Metadata
Title
Enhancing ADHD Medication Adherence: Challenges and Opportunities
Authors
Alice Charach
Rebeca Fernandez
Publication date
01-07-2013
Publisher
Springer US
Published in
Current Psychiatry Reports / Issue 7/2013
Print ISSN: 1523-3812
Electronic ISSN: 1535-1645
DOI
https://doi.org/10.1007/s11920-013-0371-6

Other articles of this Issue 7/2013

Current Psychiatry Reports 7/2013 Go to the issue

Attention-Deficit Disorder (R Bussing, Section Editor)

The Comorbidity of ADHD and Bipolar Disorder: Any Less Confusion?

Geriatric Disorders (H Lavretsky, Section Editor)

Palliative Care Psychiatry: Update on an Emerging Dimension of Psychiatric Practice

Geriatric Disorders (H Lavretsky, Section Editor)

Caregiver Health: Health of Caregivers of Alzheimer’s and Other Dementia Patients

Mood Disorders (SM Strakowski, Section Editor)

When do you Prescribe Antidepressants to Depressed Children?

Mood Disorders (SM Strakowski, Section Editor)

What Is the Role of Brain Stimulation Therapies in the Treatment of Depression?

Attention-Deficit Disorder (R Bussing, Section Editor)

Stimulant Prescription Cautions: Addressing Misuse, Diversion and Malingering